Nektar Therapeutics (NKTR) Misses Q1 Views on Top and Bottom
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $72.74 +1.38%
Revenue Growth %: -11.4%
Financial Fact:
License, collaboration and other: 8.37M
Today's EPS Names:
RCBC, GASS, YSG, More
Revenue Growth %: -11.4%
Financial Fact:
License, collaboration and other: 8.37M
Today's EPS Names:
RCBC, GASS, YSG, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 loss of $0.33, $0.06 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $11.3 million versus the consensus estimate of $17.2 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Methode Electronics (MEI) Tops Q1 EPS by 2c; offers guidance
- Snowflake soars 20% on earnings beat and raised guidance
- C3.ai (AI) Tops Q1 EPS by 5c; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
